Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of adjuvanted pandemic H1N1 vaccine prime and booster in children 6 to 35 months old
2009-013783-39Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GSK2340272A in influenza A virus infection (H1N1), sponsored by GSK. Primary endpoints: Superiority of 6-month homologous booster response versus post-first-dose response, Homologous hemagglutination inhibition antibody response after each priming dose and booster and 1 more. Started Feb 2010; status: completed.
02
Drugs
GSK2340272A
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on 2009-013783-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013783-39.